A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
08/2011
08/25/2011	US20110207680 Administration of Glufosfamide For The Treatment of Cancer
08/25/2011	US20110207676 Glycosylation of Molecules
08/25/2011	US20110207675 Gene fusion targeted therapy
08/25/2011	US20110207674 Antitumoral compounds
08/25/2011	US20110207673 Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution
08/25/2011	US20110207667 Efficient expression of truncated human rnaset2 in e. coli
08/25/2011	US20110207664 Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins
08/25/2011	US20110207656 MUC1, CASPASE-8, and DED-CONTAINING PROTEINS
08/25/2011	US20110207224 In vivo production of small interfering rnas that mediate gene silencing
08/25/2011	US20110207211 Expression of immunoglobulin-cytokine fusion proteins in malignant b cells
08/25/2011	US20110206792 Compositions comprising vitamins
08/25/2011	US20110206786 Acai and Iridoid Based Formulations
08/25/2011	US20110206760 Angiopoietin derived peptides
08/25/2011	US20110206757 Novel glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
08/25/2011	US20110206756 Dithiocarbamate metal chelates and methods of making and using thereof
08/25/2011	US20110206755 Methods and products for manipulating uncoupling protein expression
08/25/2011	US20110206739 Compositions and methods for the preparation of nanoemulsions
08/25/2011	US20110206737 Photosensitizer-containing composition
08/25/2011	US20110206736 Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
08/25/2011	US20110206735 Tumorigenic CancerStemCells, Methods of Isolating and Using the Same
08/25/2011	US20110206734 Hybrid scfa-hydroxyl-derivatized monosaccharides, methods of synthesis, and methods of treating disorders
08/25/2011	US20110206732 Albumin for treating cancer and a pharmaceutical composition comprising the combination of an anti-neoplastic agent and albumin
08/25/2011	US20110206725 Method for purifying protein complexes
08/25/2011	US20110206721 Fermented soy nutritional supplements including mushroom components
08/25/2011	US20110206708 Method for stimulating a therapeutic immune effect in a patient
08/25/2011	US20110206705 B7-h3 as a biomarker for diagnosing the progression and early lymph node metastasis of cancer
08/25/2011	US20110206704 Methods and compositions for modulating hepatocyte growth factor activator
08/25/2011	US20110206703 Gene signature for predicting prognosis of patients with solid tumors
08/25/2011	US20110206702 Compositions and methods for the diagnosis and treatment of tumor
08/25/2011	US20110206701 Use of anti-cs1 antibodies for treatment of rare lymphomas
08/25/2011	US20110206700 Anti-cd33 antibodies and methods for treatment of acute myeloid leukemia using the same
08/25/2011	US20110206697 Spink1 targeted therapy
08/25/2011	US20110206696 Methods for inhibiting bone loss and bone metastasis
08/25/2011	US20110206695 Antibodies for diagnosis and therapeutic treatment of prostate cancer
08/25/2011	US20110206691 Methods and Compositions for Treating Neuroblastoma
08/25/2011	US20110206690 Dimeric iap inhibitors
08/25/2011	US20110206689 Molecular Determinants Associated With Prostate Cancer And Methods Of Use Thereof
08/25/2011	US20110206683 Preservation mixture and use thereof
08/25/2011	US20110206682 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
08/25/2011	US20110206681 Binding molecules to the human ox40 receptor
08/25/2011	US20110206673 Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
08/25/2011	US20110206666 Targeting pax2 for the treatment of breast cancer
08/25/2011	US20110206665 Targeting pax2 for the treatment of breast cancer
08/25/2011	US20110206662 Anti-angiogenesis therapy for the treatment of ovarian cancer
08/25/2011	US20110206661 Trimethoxyphenyl inhibitors of tyrosine kinase
08/25/2011	US20110206660 Amino acid sequences directed against cxcr4 and other gpcrs and compounds comprising the same
08/25/2011	US20110206658 Compositions and methods for the treatment of tumor of hematopoietic origin
08/25/2011	US20110206646 Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
08/25/2011	US20110206645 Treatment of bone-related cancers using placental stem cells
08/25/2011	US20110206640 Engineered synergistic oncolytic viral symbiosis
08/25/2011	US20110206639 Replication competent viruses capable of silencing virus inhibitory factor expression
08/25/2011	US20110206617 Modified polysaccharides for drug and contrast agent delivery
08/25/2011	US20110206610 Compositions and methods for enhancing drug delivery across and into epithelial tissues
08/25/2011	US20110206608 Pharmaceutical Composition Of A Radioiodinated Benzamide Derivative And Methods Of Making Same
08/25/2011	US20110206603 Particulate materials and compositions for radio therapy
08/25/2011	CA2790692A1 Triazolones as fatty acid synthase inhibitors
08/25/2011	CA2790641A1 Deuterated pyrrolopyrimidine compounds as inhibitors of cdk4/6
08/25/2011	CA2790637A1 Pyrrolopyrimidine compounds as inhibitors of cdk4/6
08/25/2011	CA2790602A1 10'-fluorinated vinca alkaloids provide enhanced biological activity against mdr cancer cells
08/25/2011	CA2790318A1 Novel bexarotene analogs
08/25/2011	CA2790284A1 Heterocyclic compound
08/25/2011	CA2790176A1 Triazolo [4, 5 - b] pyridin derivatives
08/25/2011	CA2790155A1 Pyrazole derivatives as jak inhibitors
08/25/2011	CA2790095A1 Compositions comprising perfluorooctanoic acid
08/25/2011	CA2790070A1 Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
08/25/2011	CA2789655A1 Bicyclic compounds and their uses as dual c-src / jak inhibitors
08/25/2011	CA2789406A1 Pyrazolo piperidine derivatives as nadph oxidase inhibitors
08/25/2011	CA2789249A1 Heterocyclic compounds and uses as anticancer agents
08/25/2011	CA2787860A1 Substituted 2-imidazolidones and analogs
08/25/2011	CA2787304A1 Substituted spiroindolinones
08/25/2011	CA2786294A1 Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
08/25/2011	CA2784211A1 Neuregulin antagonists and use thereof in treating cancer
08/24/2011	EP2360254A1 Assays for screening anti-pd-1 antibodies and uses thereof
08/24/2011	EP2360253A1 RNA sequence-specific mediators of RNA interference
08/24/2011	EP2360252A1 Immunostimulatory nucleic acid molecules comprising GTCGTT motifs
08/24/2011	EP2360251A2 In vivo production of small interfering RNAs that mediate gene silencing
08/24/2011	EP2360187A1 Antibodies against HER2 truncated variant CTF-611
08/24/2011	EP2360184A2 Antibodies that bind human interleukin-18 and methods of making and using
08/24/2011	EP2360169A2 PSMA antibodies
08/24/2011	EP2360158A1 Pyrazole derivatives as jak inhibitors
08/24/2011	EP2359863A2 Isolation and use of solid tumor stem cells
08/24/2011	EP2359860A2 Polymer micelle composition for treatment of resistant cancer cells
08/24/2011	EP2359857A2 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
08/24/2011	EP2359855A2 Methods of administering anti-TNFalpha antibodies
08/24/2011	EP2359854A1 Pharmaceutical compositions and methods useful for modulating angiogenesis
08/24/2011	EP2359853A1 Pharmaceutical compositions and methods useful for modulating angiogenesis
08/24/2011	EP2359852A1 Novel cancer targeting therapy using complex of substance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
08/24/2011	EP2359849A1 Combination therapy
08/24/2011	EP2359842A1 Netrin-related compositions and uses
08/24/2011	EP2359841A2 Survivin-derived peptides and use thereof
08/24/2011	EP2359832A2 Therapeutic agents targeting the NCCA-ATP channel and methods of use thereof
08/24/2011	EP2359831A2 Therapeutic applications of pro-apoptotic benzodiazepines
08/24/2011	EP2359829A1 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
08/24/2011	EP2359825A2 Combination drug
08/24/2011	EP2359819A1 Substituted styryl benzylsulfones for treating proliferative disorders
08/24/2011	EP2359818A1 Combination of LBH589 with HSP 90 inhibitors for treating cancer
08/24/2011	EP2358748A2 Methods and compositions for specific modulation of mcl-1
08/24/2011	EP2358740A1 Cyclic peptides and uses thereof
08/24/2011	EP2358720A2 Fused ring heteroaryl kinase inhibitors
08/24/2011	EP2358718A1 Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway

1 ... 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 ... 2211